Mechanism of degrader-targeted protein ubiquitinability

• Published in: Science advances Vol. 10; no. 41; p. eado6492
• Main Authors: Crowe, Charlotte, Nakasone, Mark A, Chandler, Sarah, Craigon, Conner, Sathe, Gajanan, Tatham, Michael H, Makukhin, Nikolai, Hay, Ronald T, Ciulli, Alessio
• Format: Journal Article
• Language: English
• Published: United States 11.10.2024
• Subjects: Bromodomain Containing Proteins; Cell Cycle Proteins - chemistry; Cell Cycle Proteins - metabolism; Cryoelectron Microscopy; Humans; Lysine - chemistry; Lysine - metabolism; Models, Molecular; Protein Binding; Proteolysis; Transcription Factors - chemistry; Transcription Factors - metabolism; Ubiquitin - metabolism; Ubiquitin-Conjugating Enzymes - chemistry; Ubiquitin-Conjugating Enzymes - metabolism; Ubiquitination; Von Hippel-Lindau Tumor Suppressor Protein - chemistry; Von Hippel-Lindau Tumor Suppressor Protein - metabolism
• ISSN: 2375-2548; 2375-2548
• DOI: 10.1126/sciadv.ado6492

Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4 toward UBE2R1-ubiquitin, and Lys at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4 , with cellular degradation and ubiquitinomics confirming the importance of Lys and nearby Lys /Lys , identifying the "ubiquitination zone." Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4 for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design.